An LC-MS/MS method has been developed and validated for the analysis of six monoglutamate folates in rice. Accurate determination of folates in rice seeds required the optimisation of an extraction procedure encompassing homogenisation, heat treatment, tri-enzyme treatment (alpha-amylase, protease and deconjugase), centrifugation and ultrafiltration. The resulting extract was loaded onto a Polaris C 18-A column, followed by gradient elution and detection by tandem mass spectrometry. The validated method is sensitive, reproducible, accurate, and linear between 1 and 400 microg/100g rice (dry weight). The limit of detection and limit of quantification in diluted rice matrix ranged between 0.2 and 1.2 microg/100g and between 0.6 and 4 microg/100g, respectively, depending on the compound. Intra- and inter-day precision varied, respectively, from 1.0 to 9.1% RSD, and from 3.4 to 13.5% RSD, except for one compound (19.1% at low concentrations). The accuracy ranged from 96.9 to 115.4%. Matrix effects were compensated for by use of isotopically labelled internal standards. Most folates in rice extracts were stable when kept for 2 weeks at -20 and -80 degrees C, but degraded after three freeze-thaw cycles or at 4 degrees C, even when stored protected from light. Our validated method offers a sensitive and versatile approach to determine the level of six different monoglutamate folates in a complex matrix as rice.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.chroma.2008.11.004 | DOI Listing |
Clin Lung Cancer
November 2024
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH. Electronic address:
Background: With increased early detection efforts, surgery for early-stage lung cancer is expected to rise. Pafolacianine is the first FDA approved targeted optical imaging agent indicated as an adjunct for intraoperative identification of malignant and nonmalignant pulmonary lesions in adult patients with known or suspected cancer in the lung.
Methods: This is a retrospective review of the malignant and nonmalignant lesions identified by pafolacianine with intraoperative molecular imaging (IMI) in the multi-center Phase 2 and Phase 3 ELUCIDATE clinical trials.
J Nutr
October 2024
Division of Nutritional Sciences, Cornell University, Ithaca, NY, United States; Joan Klein Jacobs Center for Precision Nutrition and Health, Cornell University, Ithaca, NY, United States; Division of Epidemiology, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, United States; Division of Nutrition, St. John's Research Institute, Bengaluru, Karnataka, India. Electronic address:
Background: Double-fortified salt (DFS; iron, iodine) improved iron status in randomized trials and was incorporated into India's social safety net programs, suggesting opportunities to address other micronutrient deficiencies.
Objectives: To evaluate the acceptability of quadruple-fortified salt (QFS; iron, iodine, folic acid, and vitamin B) in women and their households, using a randomized crossover trial design and triangle tests.
Methods: Women 18-49 y (n = 77) and their households were randomly assigned to receive QFS or DFS in a randomized crossover design over a 3-wk period (week 1: QFS/DFS, week 2: iodized salt, week 3: DFS/QFS).
J Exp Bot
October 2024
Department of Life Science, National Institute of Technology Rourkela, Odisha 769008, India.
Ann Thorac Surg
October 2024
Center for Precision Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Division of Thoracic Surgery, Department of Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address:
Background: Clinical studies have demonstrated that intraoperative molecular imaging (IMI) with pafolacianine identifies occult pulmonary lesions that are not identified by preoperative computed tomography or by intraoperative inspection techniques in ∼20% of patients. This study describes occult lesion clinical data and evaluates characteristics so that surgeons can better incorporate this emerging technology into clinical decision making.
Methods: Participants (n = 100) enrolled in a phase 3 trial of IMI with pafolacianine during pulmonary resection (Enabling Lung Cancer Identification Using Folate Receptor Targeting [ELUCIDATE]; NCT04241315) were identified.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!